Bayer knowingly sold HIV-contaminated blood products to hemophiliacs overseas

Editorial Article

When Bayer discovered that its Factor VIII blood clotting product was contaminated with HIV, the company faced a choice that would define its ethical legacy. The decision they made—and how they made it—reveals a calculated business strategy that prioritized profits over the lives of vulnerable patients thousands of miles away.

Factor VIII was a lifesaving medication for hemophiliacs, people whose blood cannot clot naturally. In the early 1980s, as the AIDS crisis emerged, Bayer and other manufacturers realized their blood products posed a deadly risk. The virus was spreading through the blood supply, and hemophiliacs were among the hardest hit populations, with infection rates that would eventually reach catastrophic levels.

Here's where the story becomes difficult to defend. While Bayer removed its contaminated Factor VIII from the U.S. market and switched to safer heat-treated versions, it simultaneously continued selling the older, HIV-contaminated batches in Asia and Latin America throughout the decade. This wasn't an oversight or a logistics problem. Internal documents and regulatory records show the company knew exactly what it was doing.

The official response from Bayer and other manufacturers was measured and bureaucratic. They argued that their primary obligation was to the U.S. market, that international regulations differed, and that the products were appropriately labeled. Regulators in some countries were slower to respond than the FDA had been. The implicit message: what happened overseas wasn't their responsibility, and the economics of maintaining market share in developing nations justified the risk to foreign patients.

The evidence tells a different story. Documented haemophilia blood products records show that batches rejected for American distribution were systematically redirected to international markets. Patient records from clinics in these regions demonstrate infection patterns that tracked directly to these shipments. s and journalistic reporting in the 1990s uncovered internal memos where executives discussed the financial implications of the switch to safer products, revealing that cost—not safety alone—drove the timeline of change.